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clinicians and those affected by psychosis should countenance a much more
optimistic view of symptomatic outcome than was assumed when these con-
ditions were first described.
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Symptoms and Social Function
Psychotic disorders such as schizophrenia are largely defined on
the basis of abnormal mental phenomena, or symptoms; and their effect
on everyday function drives much of the illness burden on sufferers.
Studies investigating the long-term course and outcome of psychotic
disorders have focused for many decades on cohorts of people with
on-going illness, prevalent cases, and predominately those with a diag-
nosis of schizophrenia or non-affective psychosis (Hegarty et al., 1994).
This approach systematically excludes thosewho recover soon after on-
set and suggests predominately poor outcomes, skewing our under-
standing of the true long-term prognosis of these disorders (Cohen &
Cohen, 1984; WHO, 2007). A growing body of evidence suggests that
we have been too pessimistic about outcome and so give an overly
gloomy answer to the question frequently asked by family members
when their relative seeks help for the first time: what will happen?
Sources such as the World Health Organization (WHO) in their 2007
report “Recovery From Schizophrenia: An International Perspective”
show good outcomes in over half of those with psychotic disorders
followed for 12 to 26 years after diagnosis (WHO, 2007). Kraepelin’s
assertion of the deteriorating course of schizophrenia as its hallmark ap-
pears inconsistent with the data and a likely consequence of the individ-
uals with chronic conditions that his samples predominantly included
(Jablensky, 2010). Remission and recovery need now to be incorpo-
rated into models of schizophrenia (Barber, 2012).
Mortality Disparities
Despite the need to transform our overall perspective on the ex-
pected course of schizophrenia, profoundly negative outcomes remain a
serious challenge for some within this population. Life expectancy has
risen in developed countries over the last few decades (WHO, 2014) but
recent estimates suggest that peoplewith schizophrenia, as well as other
psychotic disorders, die 15 to 20 years earlier than their peers (Beary
et al., 2012; Crump et al., 2013; Hoang et al., 2013; Hoang et al.,
2011; Laursen et al., 2014; Nielsen et al., 2013; Saha et al., 2007;
Wahlbeck et al., 2011). The reasons for this disparity are unclear (Dutta
et al., 2012; Hoang et al., 2013; Hoang et al., 2011; Koivisto et al.,
2002; Rantanen et al., 2009; Saha et al., 2007) and it remains a major
public health concern (Reininghaus et al., 2014; Tiihonen et al., 2009;
van Os et al., 1997). Recent attempts to unravel clinical and social fac-
tors associated with excess mortality in this population suggest that life-
style, side effects of antipsychotic drug treatment and factors associated, May 2015 www.jonmd.com 379
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Joukamaa et al., 2006; O’Connor et al., 2014; Weinmann et al., 2009).
This paper synthesizes two lines of research from the ÆSOP-10
study, “Reappraising the long-term course and outcome of psychotic
disorders: the ÆSOP-10 study” (Morgan et al., 2014) and “Mortality
in schizophrenia and other psychoses: a 10-year follow-up of the
ÆSOP first-episode cohort” (Reininghaus et al., 2014). These report
the primary findings on course and outcome from a 10-year follow-up
of a large epidemiologically characterized cohort of 557 individuals
who experienced their first-episode psychosis a decade before. The aim
of former was to provide novel insights into three domains (i.e. clinical,
social, and service use/hospital admissions) of long-term outcomes and
trajectories (Morgan et al., 2014). The latter reported mortality in this
cohort, comparing it with that of the general population, and further in-
vestigating baseline clinical and social factors associated with an in-
creased risk of death (Reininghaus et al., 2014).
Eco-epidemiology provides a conceptual framework within
which to integrate factors spanning several layers of causation includ-
ing genetic, epigenetic, individual, familial, community, and societal
influences (Kirkbride and Jones, 2011; Susser and Susser, 1996). In
an attempt to reach and eco-epidemiological understanding of recov-
ery in affective and non-affective psychoses, we review and integrate
findings from the ÆSOP-10 study regarding the factors involved in
variation of outcomes, particularly those concerning remission, recov-
ery, and life expectancy. This has important clinical implications for
evidence-based approaches to treatment, family education (i.e. psycho
education) and long-term strength based approaches to care (Kelly
et al., 2009).
METHODS
Sample
ÆSOP-10 is a 10-year follow-up study of a cohort of 557 indi-
viduals with a first episode of psychosis who were initially identified
in two centers (i.e. southeast London, and Nottinghamshire, UK) con-
tributing to the ÆSOP study (Fearon et al., 2006; Kirkbride et al.,
2006). At baseline the researchers screened all inpatient and outpatient
mental health services (MHS) in defined catchment areas of Southeast
London and Nottingham (September 1997–August 1999), and the first
9 months of this period in Bristol, to identify eligible cases of first-
episode psychosis between the ages of 16 and 64 years (Kirkbride et al.,
2006). Morgan et al. (2014) reported on outcomes in the 532 incident
cases in the cohort; Reininghaus et al. (2014) reported on mortality in
the full cohort (n = 557). Full details of the methods of the ÆSOP-10
study appear in Morgan et al. (2014).
Follow-up
At approximately 10 years after inclusion in the baseline study,
we sought to trace, re-contact, and re-interview all cases. For those
who were in contact with MHS, we sought to make contact and invite
them to participate via their current clinical teams. For those who were
not, letters were sent to their last known address inviting them to partic-
ipate. Non-responders were sent a further letter 2 weeks later, and, if
necessary, researchers made a maximum of up to three visits to the ad-
dress (morning, afternoon, and evening) to make initial contact. For
those who had moved address (and for whom general practitioner
[GP] contact details were available), they sought to make contact and
invite them to participate via their GP.
Mortality
We identified all occurrences of death and emigration in the
cohort over a combined total of 5184 person years of follow-up until
12 December 2012 (mean length of follow-up 10.0 years, SD = 2.3)
via a tracing procedure conducted on their behalf by the Office for380 www.jonmd.comNational Statistics (ONS) for England and Wales and the General Reg-
ister Office (GRO) for Scotland using name, sex, date of birth, and the
last known address (Morgan et al., 2014). For all identified deaths, prin-
cipal underlying causes of death were determined according to the In-
ternational Classification of Diseases, 10th revision (ICD-10) (World
Health Organization, 1992), as recorded on copies of death certificates
obtained from ONS. These are grouped into three broad categories (using
ICD-10 codes): natural causes to refer to the disease which initiated
the train of events directly leading to death (A00-Q99), unnatural (or
external) causes to refer to the circumstances of the accident or vio-
lence which produced the fatal injury (U50.9, V01-Y89) (World Health
Organization, 1992), and unknown causes to refer to symptoms, signs
and abnormal clinical and laboratory findings not elsewhere classi-
fied (R00-R99) (World Health Organization, 1992). Unnatural causes
of death included accidents (V01-X59) and suicide (X60-X84, Y10-
Y34). Consistent with the classification of causes of death by ONS,
both intentional self-harm (X60-X84) and events of undetermined in-
tent (Y10-Y34) were coded as suicide. The underlying cause of death
recorded on copies of death certificates was further ascertained from
information collated from clinical records at follow-up using an ex-
tended version of the World Health Organization (WHO) Life Chart
(Morgan et al., 2014; Sartorius et al., 1996; WHO, 2014).
Detailed information on socio-demographic characteristics (in-
cluding sex, age, and ethnicity), clinical presentation (including diagno-
sis, duration of untreated psychosis (DUP), and illicit drug use in past
year), and social factors (including education, employment, involvement
of family at first contact with MHS) was collected at baseline (Morgan
et al., 2006a). Data on time to first remission were collected at
follow-up using the extended version of the WHO Life Chart (Morgan
et al., 2014; Sartorius et al., 1996).Mortality rates in the population at risk
for all-, natural- and unnatural-cause and population estimates stratified
by sex, age band, year, and the Census Area Statistics (CAS) wards in
Lambeth and Southwark in south east London (33 CAS wards) and
Nottinghamshire (95 CAS wards), in which cases were initially identi-
fied, were obtained from ONS for the duration of the follow-up period.
Symptoms (Remission and Recovery)
In line with Andreasen et al. (2005), remission was defined for
this study as absence of overt psychotic symptoms (operationalized
as a score of 2 or 3 on Rating Scale 2 in the SCAN; 0 = absence,
1 = symptom occurred, but fleeting, 2 = symptom definitely present,
3 = symptom present more or less continuously) for a period of at
least 6 months. Symptom recovery was defined as sustained remission
for 2 or more years.
Social
Information on sociodemographic markers of social function
and integration across a number of domains (i.e. housing, employ-
ment, relationships, education, and social networks) during and at
follow-up was collected using the Life Chart (Supplementary Table 2,
http://links.lww.com/JNMD/A4 inMorgan et al., 2014). In this previous
publication the researchers present illustrative data on employment and
relationship status as the key markers used to assess social inclusion.
Analysis
Symptoms and Social Function
Differences in primary outcomes were compared by sex, baseline
diagnosis (non-affective vs. affective) and study center using chi-square
tests, t-tests, ANOVAs and rank sum tests as appropriate. For time to first
remission Kaplan-Meier survival curves and log-rank tests were used.
Mortality
Researchers constructed Kaplan-Meier plots and used Cox re-
gression to inspect variation in risk of death over time according to© 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. Core Sample by Baseline Demographic and Clinical
Characteristics (Derived From Supplementary Table 3,
http://links.lww.com/JNMD/A4 in Morgan et al., 2014)
Length of follow-up
Mean (years) 10.7
SD 1.17
Administrative outcome % of Sample
Re-interview 193 49.9%
Declined 156 40.3%
No contact (unable to trace or contact) 38 9.8%
Sex
Men 215 55.6%
Women 172 44.4%
Baseline age
Mean (years) 30.3
SD 10.2
Ethnicity
White British 167 43.2%
Other white 25 6.5%
Black Caribbean 108 27.9%
Black African 45 11.6%
Asian (all) 22 5.7%
Other 20 5.2%
Center
Nottingham 157 40.6%
London 230 59.4%
Baseline diagnosis
Non-affective 277 71.6%
Affective 110 28.4%
Baseline employment (7 missing, n = 381)
Employed 90 23.6%
Economically inactive 68 17.9%
Unemployed 223 58.5%
Core sample (data 8+ yrs) n = 387.
TABLE 2. Core Sample by Clinical and Social Outcomes
(Derived From Table 2 and Supplementary Table 5,
http://links.lww.com/JNMD/A4 in Morgan et al., 2014)
Time to remission (n = 326)
Median (weeks) 17.5
IQR 5.6–425.4
Course (n = 345) % of n
No episodes 43 12.5%
Episodic 69 20%
Neither 153 44.3%
Continuous 80 23.2%
Recovered (symptoms) (n = 303)
Yes 140 46.2%
No 163 53.8%
% of time employed (n = 290)
>75% 34 11.7%
25–75% 48 16.6%
<25% 208 71.7%
Employed at follow-up (n = 295)
Yes 66 22.4%
No 229 77.6%
Main relationship status (n = 307)
In relationship 89 29%
Not in relationship 218 71%
In relationship at follow-up (n = 300)
Yes 95 31.7%
No 205 68.3%
Core sample (data 8+ yrs) n = 387.
The Journal of Nervous and Mental Disease • Volume 203, Number 5, May 2015 Psychosis Outcomes in ÆSOP-10socio-demographic, clinical, and social characteristics. Log-rank tests
were used to examine whether probability of death over time varied
by socio-demographic, clinical, and social characteristics. Poisson
regression was used to quantify the effect of these characteristics on
risk of all-, natural-, and unnatural-cause mortality in people with
first-episode psychosis. Indirect standardization was used to compare
mortality risk between peoplewith first-episode psychosis and the local
general population. Full details of these methods and analysis have
been reported in Reininghaus et al. (2014).
RESULTS
Of the 532 incident cases identified at baseline, 37 (7.0%) had
died (see mortality analysis, below), 29 (5.5%) had emigrated and 8
(1.5%) were excluded based on information unavailable at baseline.
Of the 458 remaining, 412 (90.0%) were successfully traced and 219
(53.2%) were re-interviewed. Of the remaining 193, 4 (1.0%) lacked
capacity (because of dementia or head trauma), and 189 (45.8%) could
not be contacted or declined re-interview. Those who had died tended
to be older and were more likely to be men; those who had emigrated
were more likely to be of black African ethnicity and from the London
cohort. Those who were not traceable tended to be men and had a diag-
nosis of a non-affective psychosis (Table 1 in Morgan et al., 2014).
After removing those who had died, emigrated or been excluded,
useable information on clinical course and outcome across one or more© 2015 Wolters Kluwer Health, Inc. All rights reserved.of the three domains was available on 387 cases for at least 8 years of
follow-up (the core analytic sample, see Table 1), with a mean length
of follow-up of 10.7 years (SD 1.2, range 8–14) (Morgan et al., 2014).
There was little evidence of selection bias in terms of those with
and without follow-up information over 8 years or more (Supplemen-
tary Table 3, http://links.lww.com/JNMD/A4 in Morgan et al., 2014).
Individuals whowere re-interviewed were more likely to have a slightly
shorter length of follow-up and were more likely to have been from the
London center (Supplementary Table 4, http://links.lww.com/JNMD/A4
in Morgan et al., 2014).
Long-term Course and Outcome
Therewas marked variability in clinical course (Table 2; Morgan
et al., 2014), ranging from the 80 (23% of 345, missing 42) cases who
did not experience a remission of psychotic symptoms (6 months or
more) at any point during the follow-up, to the 43 (13% of 345) cases
who had a remission of symptoms within 6 months of first contact
and remained symptom free for the duration of the follow-up. An addi-
tional 69 (20% of 345) did have further episodes after initial remission,
but none that lasted more than 6 months. The remaining cases (153,
44% of 345) formed an intermediate group that had at least one remis-
sion and at least one episode lasting more than 6 months (i.e., neither
continuous nor episodic). In total, 265 (77%) of the cases had at least
one remission during the follow-up period. At follow-up, 213 (65%
of 326, missing 61) were not experiencing psychotic symptoms and
140 (46% of 303 on whom complete data were available, missing 84)
had been free of psychotic symptoms for the preceding 2 years or more,
thus meeting criteria for symptom recovery. Among cases for which
therewas reliable information (228; 75% of 303 with data on recovery),
56% of those who recovered (57 of 101) had been prescribed anti-
psychotic medication in the 2 years before follow-up, in contrast withwww.jonmd.com 381
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that all cases were, at some point, prescribed anti-psychotic medication
(Table 2 and Supplementary Figure 1, http://links.lww.com/JNMD/A4
in Morgan et al., 2014).
Social
Relationship status and employment were used as indicators of
social outcomes and compared with data from previous studies. There
was strong evidence that social exclusion present among cases at base-
line (28% of cases employed vs. 55% of controls, 29% in a relationship
vs. 61% of controls (Morgan et al., 2008) persisted at follow-up (22% of
cases employed and 32% in a relationship). Only 34 (12% of 290) cases
had been in paid work for over 75% of the follow-up period. A slightly
larger but still small proportion had been employed for between 25%
and 75% of the follow-up (48; 17%). The majority had been employed
for less than 25% of the 10-year follow-up (208, 72%). With regard to
relationship status, a majority of cases were single for most of the
follow-up (218, 71%) and at follow-up (205, 68%). Those with a base-
line diagnosis of non-affective psychosis and those incepted in London
were more likely to experience poor outcomes in these domains
(Table 3 in Morgan et al. 2014). These findings suggest that social ex-
clusion emerges either before or shortly after onset and persists over the
long term. Only 15% (34 of 223) of the cases in the core sample that
were unemployed at baseline were in employment at follow-up. Simi-
larly, of those not in a relationship at baseline, only 16% (33 of 210)
were in a relationship at follow-up.
Mortality
There was evidence of excess mortality over the follow-up pe-
riod. Of the 557 cases with first-episode psychosis identified at base-
line, 8 were excluded based on additional diagnostic information not
available at baseline. Of the remaining 549 cases, 39 (7.1%) cases had
died, 15 (2.7%) because of natural causes, 21 (3.8%) because of unnatu-
ral causes, and 3 (0.6%) because of unknown causes of death. Cases with
a natural cause of death predominantly died of diseases of the digestive
system (n = 7, 1.3%), with 3 (0.6%) of these having died of definite
alcohol-related causes and 3 (0.6%, 0.05%) from probable alcohol-
related causes (Supplementary Table 1, http://links.lww.com/JNMD/A5
in Reininghaus et al., 2014). The most common unnatural cause
of death was suicide (n = 13, 2.4%) (Supplementary Table 1,
http://links.lww.com/JNMD/A5 in Reininghaus et al., 2014). Of the
17 cases with an unnatural cause of death for whom reliable informa-
tion was obtained on baseline illicit drug use (81.0% of 21 who had
died of unnatural causes), 12 (70.6% of 17) had reported use of illicit
drugs in the previous year (cannabis use, n = 7 (41.1%); amphetamine
use, n = 1 (5.9%); multiple substance use, n = 4 (23.5%)). At follow-up,FIGURE 1. Time to first remission and illicit drug use at baseline; rates of mort
382 www.jonmd.com3 cases (0.6%) had died of accidental poisoning (Supplementary
Table 1, http://links.lww.com/JNMD/A5 in Reininghaus et al., 2014).
Therewas a decreased risk of unnatural-cause mortality in women
compared with men after controlling for age at baseline (Table 2 in
Reininghaus et al., 2014) and a reduced risk of all-cause and natural-
cause mortality in younger cases. There were no statistically signifi-
cant differences in risk of mortality by broad ethnic group (Table 2 in
Reininghaus et al., 2014).
Mortality in the ÆSOP Cohort Compared with the Local
General Population
SMRs (standardized mortality ratios) for all, natural, and unnat-
ural causes of death were reported (Table 3 in Reininghaus et al., 2014).
There was an almost fourfold increase in all-cause mortality in the co-
hort compared with that in the general population (SMR = 3.6, 95%
CI 2.6–4.9). All-cause SMRs were of similar magnitude in the two
study sites (London and Nottingham), slightly more pronounced in
men (SMR = 4.1, 95% CI 2.8–5.9) than in women (SMR = 2.8, 95%
CI 1.6–5.1), and lower for cases in higher age bands. When broken
down by natural and unnatural causes of death, the increase in natural-
cause mortality was approximately twofold, compared with a 13-fold in-
crease in unnatural-cause mortality. There was no strong evidence that
unnatural-cause SMRs varied by place, sex, or age and SMRs remained
high for older cases (aged 60–74). On examination risk of suicidewas the
most common unnatural cause of death in the cohort; there was a 20-fold
increase comparedwith that in the local general population (SMR=20.0,
95% CI 11.7–34.5) (Table 3 in Reininghaus et al., 2014).
All-, Natural- and Unnatural-Cause Mortality by Clinical
and Social Factors
The Kaplan-Meier survival curves show evidence that a long DUP
(Supplementary Figure 3, http://links.lww.com/JNMD/A5 inReininghaus
et al., 2014) and a long time to first remission (Supplementary Figure 4,
http://links.lww.com/JNMD/A5 in Reininghaus et al., 2014) were associ-
ated with an increased risk of all- and natural-cause death over time. Find-
ings from Cox regression indicated that the association between time to
first remission and natural-cause death over time held after adjusting
for age at baseline and sex (Fig. 1; Adj. HR 6.76; p = 0.02) (Supple-
mentary Table 4, http://links.lww.com/JNMD/A5 in Reininghaus et al.,
2014). Further, illicit drug use in the year before baseline was asso-
ciated with an increased risk of all- and unnatural-cause death over
time, while adjusting for age and sex (Fig. 1; all-cause Adj. HR 2.30;
p = 0.04 and unnatural-cause Adj. HR 3.04; p = 0.05) (Supplementary
Table 4, http://links.lww.com/JNMD/A5 and Supplementary Figure 5,
http://links.lww.com/JNMD/A5 in Reininghaus et al., 2014). In addi-
tion, researchers found strong evidence of reduced risk of unnaturalality by cause.
© 2015 Wolters Kluwer Health, Inc. All rights reserved.
The Journal of Nervous and Mental Disease • Volume 203, Number 5, May 2015 Psychosis Outcomes in ÆSOP-10death over time for caseswith full family involvement at first contact with
services (family actively sought help for individual), which remained when
adjusted for age at baseline and sex, as reflected in Figure 2 (Adj. HR
0.09; p = 0.02) (Supplementary Table 4, http://links.lww.com/JNMD/A5
andSupplementaryFigure 6, http://links.lww.com/JNMD/A5 inReininghaus
et al., 2014).
Rate ratios for all-, natural- and unnatural-cause mortality by
clinical and social factors are shown in Table 4 in Reininghaus et al.
(2014). Although a long DUP was associated with an increased risk
of all- and natural-cause mortality in unadjusted analyses, this associa-
tion was diminished and ceased to be statistically significant when
adjusting for age at baseline and sex. Similarly, after adjusting for these
factors, the association between a long time to first remission and in-
creased risk of all-cause mortality was no longer significant. However,
the rate ratio for a long time to first remission and increased risk of
natural-cause mortality held after adjusting for age and sex (Adj.
RR 6.61; p = 0.02) (see Table 4 in Reininghaus et al., 2014). Further,
illicit drug use was associated with a twofold to almost fourfold in-
creased risk of all- and unnatural-cause mortality, respectively, while
controlling for age and sex (all-cause Adj. RR 2.31; p = 0.04 and
unnatural-cause Adj. RR 3.78; p = 0.03) (see Table 4 in Reininghaus
et al., 2014). However, researchers found some evidence that the asso-
ciation between illicit drug use and unnatural-cause mortality was
confounded by lack of family involvement at first contact (LRT,
χ2 = 7.22, p = 0.03). Although this association was attenuated, there
was still some evidence of an approximately threefold increased risk
of unnatural-cause mortality in cases using illicit drugs (Adj. RR
3.25; p = 0.06). Finally, a reduced risk of unnatural-cause mortality
was found in cases with full family involvement when compared
with those with no family involvement at first contact with services,
while controlling for age and sex (Adj. RR 0.09; p = 0.02). This
association held when further adjusted for illicit drug use (χ2 = 2.65,
p = 0.10) (Table 4 in Reininghaus et al., 2014).DISCUSSION
We have distilled the results of two contrasting aspects of the
ÆSOP-10 follow-up, mortality and illness course, the latter in terms
of symptomatic and functional measures. The most striking findings
concern the high rate of symptomatic recovery at approximately 50%
in contrast to the less encouraging social outcomes, with only around
15% of individuals having improved work or relationship status byFIGURE 2. Family involvement at first contact; rates of mortality by cause.
© 2015 Wolters Kluwer Health, Inc. All rights reserved.follow-up. The notable points from the Reininghaus et al. (2014) paper
stand in stark contrast—as two extremes. First, compared with no fam-
ily involvement, therewas a marked 90% reduction in risk of unnatural-
cause mortality when full family involvement was present at first con-
tact. Second, and in contrast, there was a sevenfold increase in risk of
natural-cause mortality when the time to first remission was >2 years
and a threefold increase in risk of unnatural-cause mortality with illicit
drug use before baseline.
Methodological Considerations
ÆSOP-10 sought to minimize selection bias due to attrition by
making exhaustive efforts to trace cases and by using official sources
to establish deaths and emigrations. Thus, the whereabouts and/or status
of over 90% of the original cohort were ascertained and therewas surpris-
ingly little evidence that selection bias through differential follow-up was
a major problem.
To address the challenge of reducing information (recall) bias,
researchers used multiple sources of information to complete the Life
Chart, and established clinical ratings by consensus after careful consid-
eration of all available data (Morgan et al., 2014).
Mortality
Deaths in this cohort were notably elevated when compared with
the general population. In absolute terms, though, the number of deaths
overall was small and consequently confidence limits were wide. How-
ever, the elevated mortality is in line with other data and continued
follow-up of this cohort would be an effective approach to increasing
the precision of these findings. An important factor that was not mea-
sured at baseline in this study was alcohol use. Nonetheless, by utilizing
person tracing procedures (ONS and GRO), researchers were able to
examine alcohol where implicated in a principal underlying cause of
death. Still, insufficient data exist in this study to form a firm con-
clusion regarding its role as a risk factor for mortality (Reininghaus
et al., 2014).
The most noteworthy strength of ÆSOP-10 is that it is a large
epidemiological cohort of unselected first-episode cases of psychoses
from clearly defined geographic areas. Examining factors based spe-
cifically on local population variances may lend itself to an improved
understanding of not only the risk factors implicated, but also those
more pronounced within specific areas. This may help better inform
local intervention services on issues more specific to their area (Ezzatiwww.jonmd.com 383
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et al., 2014; Yang et al., 2013).Symptoms and Social Function (Long-term Course and
Outcome of Psychosis)
There was considerable heterogeneity in clinical course and out-
come. Although similar in diversity to previous studies, the proportion
of cases experiencing a continuous course was notably lower (e.g., 23%
in ÆSOP-10 at 8 years vs. 33% for all psychoses at 15 years in the
WHO International Study of Schizophrenia (ISoS); Harrison et al.,
2001). When we specifically consider recovery, approximately half had
not experienced clinically significant symptoms in the 2 years before
follow-up (as reflected in Fig. 3). Despite some not meeting these
defining 2-year criteria for recovery, a full two thirds of the cohort
were experiencing no psychotic symptoms at the time of follow-up
(Morgan et al., 2014). It was challenging to directly compare this with
previous studies because of differences in the assessment of course
and recovery, as well as the inclusion of those with affective psychoses
and psychoses associated with drug use (but not intoxication), two first-
episode studies conducted in Europe also reported the proportion of
people who remained symptom free after remission of first episode;
these findings were in line with ours at 7% (Möller et al., 2010) and
12% (Wiersma et al., 1998), respectively.
The proportion of people with a first-episode of psychosis who
“recover” in previous studies ranges from 20% (Ciompi, 1980) to
61% (WHO, 2007), with higher estimated proportions from studies of
incident cases of all psychoses (Harrison et al., 2001) and those where
recovery was defined cross-sectionally, without requiring absence of
symptoms for in excess of 2 years (Thara et al., 1994). Despite the
more conservative definition of recovery used in this study (absence
of clinically overt psychotic symptoms greater than 2 years), the find-
ings of 54% overall (37% for non-affective) is within the range of
these previous studies and further supported by a 5-year follow-up
study of 118 first-episode schizophrenia cases reflecting 47% recovery
(Robinson et al., 2004). This body of evidence would seem to suggest
that the research relating to outcomes in schizophrenia and other psy-
choses, conducted before the more recent long-term course and out-
come studies, has painted an overly pessimistic picture of the clinicalFIGURE 3. ÆSOP-10 study clinical course and outcome.
384 www.jonmd.comcourse for individuals experiencing psychosis. It is notable and en-
couraging that the findings of this study suggest that almost half of
persons developing psychosis will symptomatically recover within
8 years, and of those who do recover nearly 20% will do so within
6 months of contact with services. Non-affective disorders often follow
a less favorable trajectory when compared with affective disorders
(Harrow et al., 2005). Even within this population, ÆSOP-10 showed
that approximately 40% of individuals with non-affective diagnoses
recovered symptomatically (Morgan et al., 2014). All participants in
this study were, at some point, prescribed at least one anti-psychotic
drug (see results). However, it remains a moot point as to how long
prescriptions should continue when people have recovered.
Importantly, Morgan et al. (2014) were able to distinguish be-
tween social and symptomatic forms of recovery, which highlighted
the disparity between these. Whereas symptomatic outcomes were
better than in previous studies, social outcomes were poor for most
cases despite the relatively high rates of remission and recovery. Ap-
proximately 22% of individuals were employed at follow-up in contrast
to 49% and 67% in the general population for the two areas studied
(Morgan et al., 2014). Further, there was a more dramatic contrast
in employment at follow-up between non-affective (16%) and affective
(39%) disorders. Other studies have reported similar findings (Morgan
et al., 2014; White et al., 2009). These disparities are likely to be multi-
factorial and will require further study to tease apart the most significant
associations and determine how we might improve support services
and public health policy to facilitate an increase in social inclusion for
individuals recovering from psychotic disorders.
Mortality
The results reinforce the gloomy findings from previous studies.
At the forefront is the fact that deaths from unnatural-causes were
markedly elevated (13-fold compared with the general population),
with suicide being the leading cause of death in this category (20-fold);
deaths from natural-causes were still elevated, but to a lesser extent
(twofold). Women had a reduced risk of death by unnatural-cause
(approximately 70% reduction in rate ratio (HR)) than their male
counterparts. A more encouraging finding is that the risk of
unnatural-cause mortality was reduced by 90% when full family in-
volvement exists at time of first contact with services. However, the© 2015 Wolters Kluwer Health, Inc. All rights reserved.
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note. Most notably, natural-cause mortality increased sevenfold with a
longer time to first remission (>2 years), and unnatural-cause mortality
increased threefold with illicit drug use in the year before baseline.
The finding that full family involvement at first contact may
have such a profound impact on reducing the risk of unnatural-cause
mortality suggests that appropriate involvement of family and care-
givers could be an important element of risk management and suicide
prevention in early psychosis (Hunt et al., 2006; Power et al., 2003).
Further research should also be conducted because family involvement
may be a proxy for other factors such as socio-economic status, family
cohesion, and level of education. However, in line with previous re-
search exploring the risk of suicide over a longer duration (Dutta et al.,
2010), it may be reasonable to infer that continued family and caregiver
involvement, beyond the initial contact, will be important to maintaining
a reduced risk of unnatural-cause mortality.CONCLUSIONS
Symptoms and Social Function
Findings to date fromÆSOP-10, a follow-up of a large cohort of
cases with first-episode psychosis highlight several key elements of
recovery. These results suggest that researchers, clinicians and those af-
fected by psychosis should take a much more optimistic view of symp-
tomatic outcome than was assumed when these conditions were first
described. Symptom remission and recovery seem more common than
historically believed, but distinguishing symptomatic and social recov-
ery is important. In this study, social inclusion—even when symptom-
atic recovery has occurred—remained more elusive. Dissemination of
this research to care providers working with patients experiencing psy-
chotic disordersmay facilitate amuchmore appropriate viewof symptom-
atic outcome and the challenging contrast of social outcome. There is a
clear need to continue the research in long-term follow-up of early psycho-
ses studies to more effectively identify tractable predictors of clinical and
social outcome. The accumulated results of these studies may later be ap-
plied to improve the trajectories of psychoses by appropriately adjusting
the design of treatment plans and support services (Morgan et al., 2014).
Mortality
The findings confirm the adverse mortality gap experienced by
those with schizophrenia and other psychoses, and further show this
may be even greater for unnatural-cause mortality than previously re-
ported. They also highlight specific areas that warrant additional focus.
The 90% reduction in risk reported for unnatural-cause mortality, when
full family involvement was present at first contact, provides an area that
can be further assessed as to its importance over the life course. This may
also be useful for the encouragement of early psychoses programs, as
well as other care providers, to design treatment plans that specifically
focus on the inclusion and support of family and caregivers. The seven-
fold increase in risk of natural-cause mortality with a longer time to first
remission, and the threefold increase in risk of unnatural-cause mortality
with illicit drug use in the year before baseline, provide two specific areas
for the future study of tractable clinical and social risk factors that may
contribute to excess mortality.
The mortality results, coupled with those relating to symptom
and social function, shine light on a path forward indicating that early
intervention, family/caregiver inclusion, and dual diagnosis services
may play an important role in reducing mortality rates, further increas-
ing remission and making recovery the most likely outcome for those
experiencing psychosis (Reininghaus et al., 2014).DISCLOSURES
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